8-K: FDA Declines Approval for Vanda's Tradipitant in Gastroparesis, Citing Need for Additional Studies

The FDA has declined to approve Vanda Pharmaceuticals' tradipitant for gastroparesis, requesting additional studies despite existing evidence of efficacy.

Summary

• The FDA issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals, declining to approve their New Drug Application (NDA) for tradipitant to treat gastroparesis.
• The FDA's decision was made despite Vanda providing evidence from two placebo-controlled studies, an open-label study, and real-world data from an expanded access program.
• The FDA's CRL suggested additional studies with a design and duration that Vanda believes are inconsistent with expert advice and the scientific understanding of gastroparesis.
• The FDA's review process was delayed by more than 185 days, exceeding the 180-day requirement under the Food Drug and Cosmetic Act (FDCA).
• Vanda believes that its tradipitant application met the substantial evidence of efficacy standard and has a favorable benefit-risk profile.
• Vanda has repeatedly requested an expert advisory committee to review the application, but the FDA has refused.
• Vanda plans to submit a separate NDA for tradipitant for the prevention of vomiting in motion sickness later this year.
• Vanda will continue to support the expanded access program for gastroparesis patients.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the FDA's rejection of the drug application and the delay in the review process. While Vanda expresses confidence in their data, the overall tone is disappointing.

Positives

• Vanda has a separate NDA planned for tradipitant for motion sickness.
• Vanda will continue to support the expanded access program for gastroparesis patients.
• Vanda believes the tradipitant application met the substantial evidence of efficacy standard.

Negatives

• The FDA declined to approve Vanda's tradipitant for gastroparesis.
• The FDA's review process was delayed by more than 185 days.
• The FDA suggested additional studies that Vanda considers inappropriate.
• The FDA refused to convene an expert advisory committee to review the application.

Risks

• The FDA may not approve the tradipitant application for motion sickness.
• The additional studies requested by the FDA for gastroparesis may be costly and time-consuming.
• There is no guarantee that the FDA will approve tradipitant for gastroparesis in the future.
• The delay in the FDA's decision could negatively impact investor confidence.

Future Outlook

Vanda plans to submit a separate NDA for tradipitant for the prevention of vomiting in motion sickness later this year and will continue to pursue marketing authorization for tradipitant for gastroparesis.

Management Comments

• Vanda believes that the tradipitant application has met the substantial evidence of efficacy standard with a favorable benefit risk profile for the treatment of patients with gastroparesis.
• Vanda has repeatedly requested that the FDA convene an expert advisory committee to review the application and advise the Commissioner on the approvability of this application, the FDA has refused to do so.

Industry Context

The FDA's rejection of tradipitant highlights the challenges in obtaining regulatory approval for new treatments, particularly for conditions like gastroparesis where there are limited existing options. This decision may impact investor sentiment towards other companies developing treatments for similar conditions.

Comparison to Industry Standards

• The FDA's decision to request additional studies is not uncommon, but the specific design and duration requirements are being questioned by Vanda and are inconsistent with the advice of key experts in the field.
• The delay of more than 185 days in the FDA's review process is significantly longer than the 180-day requirement specified by the Food Drug and Cosmetic Act (FDCA), which is unusual.
• The lack of an expert advisory committee review is also unusual, as these committees are often convened for complex or controversial drug applications.
• Other companies such as Evoke Pharma with Gimoti have faced similar challenges in the gastroparesis space, highlighting the difficulty in developing effective treatments and navigating the regulatory landscape.

Stakeholder Impact

• Shareholders may experience a negative impact due to the FDA's rejection of the tradipitant application.
• Patients with gastroparesis may be disappointed by the delay in the potential approval of tradipitant.
• Employees of Vanda may face uncertainty due to the regulatory setback.

Next Steps

• Vanda plans to submit a separate NDA for tradipitant for the prevention of vomiting in motion sickness later this year.
• Vanda will continue to pursue the marketing authorization for tradipitant for gastroparesis.
• Vanda will continue to support the expanded access program for gastroparesis patients.

Key Dates

Keywords

Tradipitant, Gastroparesis, FDA, Complete Response Letter, New Drug Application, Vanda Pharmaceuticals, Motion Sickness, Drug Approval, Clinical Trials, Biopharmaceutical